Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis

被引:0
作者
Kaya, Zuhre [1 ]
Alici, Nurettin [1 ]
Kirkiz, Serap [1 ]
Kocak, Ulker [1 ]
机构
[1] Gazi Univ, Fac Med, Dept Pediat Hematol, Ankara, Turkiye
关键词
Febrile neutropenia; Children; Leukemia; Risk factor; Prophylaxis; CHEMOTHERAPY-INDUCED NEUTROPENIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-PATIENTS; CANCER; EPISODES; BACTEREMIA;
D O I
10.4274/tjh.galenos.2023.2023.0116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to identify risk factors and improve preventive strategies for febrile neutropenia (FEN) in children with leukemia who were receiving ciprofloxacin prophylaxis. The study included 100 children with leukemia [n=80 with acute lymphoblastic leukemia and n=20 with acute myeloblastic leukemia (AML)]. Patients were divided into two groups based on whether they had three or fewer FEN episodes (Group 1) or more than three FEN episodes (Group 2). Group 1 contained 63 (63%) of the 100 patients, while Group 2 contained 37 (37%). Older age (=7 years), leukemia type, prolonged neutropenia (>10 days), and the presence of neutropenia and hypogammaglobulinemia at diagnosis were all risk factors for having more than three FEN episodes. Our findings suggest that, in addition to ciprofloxacin prophylaxis, identifying risk factors and improving preventive strategies could help reduce FEN episodes in children with leukemia.
引用
收藏
页码:183 / 186
页数:4
相关论文
共 50 条
  • [21] Febrile Neutropenia Syndromes in Children: Risk Factors and Outcomes of Primary, Prolonged, and Recurrent Fever
    Alali, Muayad
    David, Michael Z.
    Ham, Sandra A.
    Danziger-Isakov, Lara
    Pisano, Jennifer
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (07) : E962 - E971
  • [22] DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma
    Ozdemir, Nihal
    Celkan, Tiraje
    Baris, Safa
    Batar, Bahadir
    Guven, Mehmet
    LEUKEMIA RESEARCH, 2012, 36 (05) : 565 - 569
  • [23] Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia
    Gilles Freyer
    Ewa Kalinka-Warzocha
    Konstantinos Syrigos
    Mihai Marinca
    Giuseppe Tonini
    Say Liang Ng
    Zee Wan Wong
    Antonio Salar
    Guenther Steger
    Mahmoud Abdelsalam
    Lucy DeCosta
    Zsolt Szabo
    Medical Oncology, 2015, 32
  • [24] Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia
    Freyer, Gilles
    Kalinka-Warzocha, Ewa
    Syrigos, Konstantinos
    Marinca, Mihai
    Tonini, Giuseppe
    Ng, Say Liang
    Wong, Zee Wan
    Salar, Antonio
    Steger, Guenther
    Abdelsalam, Mahmoud
    DeCosta, Lucy
    Szabo, Zsolt
    MEDICAL ONCOLOGY, 2015, 32 (10)
  • [25] Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer
    Ravi K. Goyal
    Spiros Tzivelekis
    Kenneth J. Rothman
    Sean D. Candrilli
    James A. Kaye
    Supportive Care in Cancer, 2018, 26 : 539 - 548
  • [26] Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer
    Goyal, Ravi K.
    Tzivelekis, Spiros
    Rothman, Kenneth J.
    Candrilli, Sean D.
    Kaye, James A.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (02) : 539 - 548
  • [27] Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China
    Zheng, Wenshuai
    Chen, Zhaoguang
    Zhu, Shibin
    Cheng, Longcan
    Hu, Yalei
    Yang, Yuhui
    Tan, Min
    Ning, Hongmei
    Guan, Lixun
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [28] Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China
    Wenshuai Zheng
    Zhaoguang Chen
    Shibin Zhu
    Longcan Cheng
    Yalei Hu
    Yuhui Yang
    Min Tan
    Hongmei Ning
    Lixun Guan
    Supportive Care in Cancer, 2024, 32
  • [29] The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum
    Fujiwara, Takumi
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kawamura, Takahisa
    Mamesaya, Nobuaki
    Kotake, Mie
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Taira, Tetsuhiko
    Murakami, Haruyasu
    Omae, Katsuhiro
    Mori, Keita
    Endo, Masahiro
    Takahashi, Toshiaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1229 - 1237
  • [30] Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India
    Rajendranath, R.
    Balasubramaniyum, V. K. K.
    Vijayakumar, V.
    Ganesan, P.
    Tenali, G. S.
    INDIAN JOURNAL OF CANCER, 2014, 51 (04) : 481 - U360